Category: Non classé

We’re thrilled to announce PEACCEL’s pioneering paper in the realm of Quantum Computing for biologics, marking a significant leap forward in pharmaceutical discovery. Our cutting-edge research, conducted in collaboration with the University of Western Australia’s esteemed Quantum Physics and Computing team – Shengxin Zhuang, John Tanner, Yusen Wu, under the great leadership of Prof Jingbo Wang, Ass. Prof Du Huynh, and Ass. Prof Weil Liu – demonstrates the untapped potential of Quantum Machine Learning (QML) in the biopharmaceutical industry.

🌐 Quantum Advantages in Computational Biology 🌐

This research underlines the significant, yet largely untapped, advantages of quantum computing in the field of computational biology. By demonstrating that QSVM can exceed the performance of classical machine learning models, we provide empirical evidence and hope for quantum advantages in real-world applications, particularly in developing safer therapeutic solutions.

🔬 Why This Matters for Pharma 🔬

In our study, we applied the quantum support vector machine (QSVM, up to 14 Qubits) to a crucial task: classifying peptides as either hemolytic or non-hemolytic. According to the French national health database, 160 drugs have been shown to induce autoimmune hemolytic anemia for the period 2012-2018, and  3,371 cases of Drug Induce Autoimmune Hemolytic anemia (DI-AIHA) were recorded (https://doi.org/10.1182/blood-2022-157730). 1% wrong class assignment means more human deaths by hemolysis. A 1% gain in accuracy in healthcare can save many lives.

The implications of this work for the pharmaceutical industry are profound. We can harness the quantum leap to expedite the development of novel biologics and transform patient care worldwide.

For more information: https://arxiv.org/abs/2402.03847

PEACCEL
Making the world disease free
Contact: AI-team@peaccel.com
http://www.peaccel.com/

We’re thrilled to share an exciting milestone at PEACCEL – our disruptive AI discovery platform for biologics is setting new benchmarks in the pharmaceutical industry. By unlocking previously inaccessible spaces, we are identifying novel, life-changing drugs that were only possible in nature 1% of the time. Imagine the potential when we can screen 1 billion molecules in a single day!

🌐 A Game-Changing Collaboration: PEACCEL & Google Cloud 🌐

Our journey has taken an exhilarating turn as we were handpicked to join the Google Startup Program. This collaboration is not just an endorsement of our innovative approach; it’s a catalyst for exponential growth and impact. Here’s what this means for the pharmaceutical industry:

1. Massive Scale Screening: From millions to over a billion molecules per day, pushing the boundaries of drug candidate identification from good to the BEST.
2. Industrial Scale AI: Our platform’s scalability is now supercharged, ready for real-world applications at an industrial level.
3. Unprecedented Computing Power: Access to a vast array of GPUs, expanding our computing capacity to accelerate drug development, reduce costs, and bring life-saving treatments to market faster.
4. Robust Infrastructure & Tools: Leveraging Google’s state-of-the-art technology to enhance our research capabilities, foster innovation and drive forward the future of drug discovery.

PEACCEL (Paris, Fr) and JWIP & Patent Services, LLC (Boston, USA) have signed a strategic partnership agreement.

As of October 2022, PEACCEL – The AI company for life sciences in Paris, and JWIP & Patent Services, LLC a Leading IP Firm in Boston, USA, combine their know-how and expertise to address the increasing needs of emerging AI-based drug discovery challenges for their large portfolio of customers and partners.
Combining the innov’SAR industrial AI platform developed by PEACCEL and the legal counsel provided by JWIP to accelerate critical collaborations and licensing between PEACCEL and key players in the pharmaceutical and chemical industries.

Continue reading “PEACCEL (Paris, Fr) and JWIP & Patent Services, LLC (Boston, USA) sign a strategic partnership to increase the chances of success of your drugs”

PEACCEL and partners underline in the June 2022 issue of the peer-
reviewed journal Frontiers in Artificial intelligence how non-linearity is crucial when
modeling metabolic pathways for the identification of biomarkers of diseases or
optimizing industrial production processes.
Exemplified for:

• The Entamoeba histolytica glycolysis, one of the major metabolic pathways of the parasite
• The peroxide detoxification pathway of Trypanosoma cruzi
• The industrial-scale penicillin fermentation process of Penicillium chrysogenum

Read more…